260 results on '"Palivizumab therapeutic use"'
Search Results
2. Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.
- Author
-
Gebretekle GB, Yeung MW, Ximenes R, Cernat A, Simmons AE, Killikelly A, Siu W, Rafferty E, Brousseau N, Tunis M, and Tuite AR
- Subjects
- Humans, Infant, Canada, Female, Antiviral Agents economics, Antiviral Agents therapeutic use, Respiratory Syncytial Virus, Human immunology, Respiratory Syncytial Virus, Human drug effects, Male, Infant, Newborn, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Infections economics, Cost-Benefit Analysis, Respiratory Syncytial Virus Vaccines economics, Respiratory Syncytial Virus Vaccines therapeutic use, Respiratory Syncytial Virus Vaccines administration & dosage, Antibodies, Monoclonal, Humanized economics, Antibodies, Monoclonal, Humanized therapeutic use, Palivizumab therapeutic use, Palivizumab economics, Quality-Adjusted Life Years
- Abstract
Background: Health Canada recently authorized the RSVpreF pregnancy vaccine and nirsevimab to protect infants against respiratory syncytial virus (RSV) disease., Objective: Assess the cost-effectiveness of RSVpreF and nirsevimab programs in preventing RSV disease in infants, compared to a palivizumab program., Methods: We used a static cohort model of a Canadian birth cohort during their first RSV season to estimate sequential incremental cost-effectiveness ratios (ICERs) in 2023 Canadian dollars per quality-adjusted life year (QALY) for nine strategies implemented over a one-year time period, from the health system and societal perspectives. Sensitivity and scenario analyses were conducted to explore the impact of uncertainties on the results., Results: All-infants nirsevimab programs averted more RSV-related outcomes than year-round RSVpreF programs, with the most RSV cases averted in a seasonal nirsevimab program with catch-up. Assuming list prices for these immunizing agents, all-infants nirsevimab and year-round RSVpreF programs were never cost-effective, with ICERs far exceeding commonly used cost-effectiveness thresholds. Seasonal nirsevimab with catch-up for infants born outside the RSV season was a cost-effective program if prioritized for infants at moderate/high-risk (ICER <$28,000 per QALY) or those living in settings with higher RSV burden and healthcare costs, such as remote communities where transport would be complex (ICER of $5700 per QALY). Using a $50,000 per QALY threshold, an all-infants nirsevimab program could be optimal if nirsevimab is priced at <$110-190 per dose. A year-round RSVpreF for all pregnant women and pregnant people plus nirsevimab for infants at high-risk was optimal if nirsevimab is priced at >$110-190 per dose and RSVpreF priced at <$60-125 per dose., Interpretation: Prophylactic interventions can substantially reduce RSV disease in infants, and more focused nirsevimab programs are the most cost-effective option at current product prices., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ellen Rafferty reports a relationship with Natural Sciences and Engineering Research Council of Canada that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Crown Copyright © 2024. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Genotype Analysis of Respiratory Syncytial Virus Before and After the COVID-19 Pandemic Using Whole-Genome Sequencing: A Prospective, Single-Center Study in Korea From 2019 to 2022.
- Author
-
Na B, Park YJ, Seo J, Park M, Baek JY, Lee JY, Kim M, Ahn JG, Lee ST, and Kang JM
- Subjects
- Humans, Prospective Studies, Republic of Korea epidemiology, Drug Resistance, Viral genetics, Antiviral Agents therapeutic use, Genome, Viral, Palivizumab therapeutic use, Female, Mutation, Male, Child, Child, Preschool, Infant, Antibodies, Monoclonal, Humanized therapeutic use, COVID-19 virology, COVID-19 epidemiology, Genotype, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections virology, Whole Genome Sequencing, SARS-CoV-2 genetics, SARS-CoV-2 isolation & purification, Respiratory Syncytial Virus, Human genetics, Respiratory Syncytial Virus, Human isolation & purification
- Abstract
Background: Respiratory syncytial virus (RSV), a highly transmissible virus, is the leading cause of lower respiratory tract infections. We examined molecular changes in the RSV genome before and after the coronavirus disease 2019 (COVID-19) pandemic in Korea, and investigated whether drug-resistant mutations were present., Methods: In this prospective, single-center study, RSV-positive respiratory samples were collected between September 2019 and December 2022. Long-read whole-genome sequencing (WGS) was performed, and the presence of known drug-resistant substitutions for palivizumab, nirsevimab, and suptavumab was investigated., Results: Overall, 288 respiratory samples were collected from 276 children. WGS data were available for 133 samples (71 and 62 samples from the pre- and post-pandemic periods, respectively). All RSV-A strains (n = 56) belonged to the GA2.3.5 (ON1) genotype, whereas all RSV-B strains (n = 77) belonged to the GB5.0.5a (BA) genotype. No significant differences in genotypes were observed between the pre- and post-pandemic periods. In addition, no notable mutations related to nirsevimab or palivizumab resistance were detected in the F gene. However, the L172Q and S173L substitutions, which are known to confer resistance to suptavumab, were present in all RSV-B samples., Conclusion: Despite the unprecedented interruption of RSV seasonality, there were no significant molecular changes in circulating RSV strains in Korea related to nirsevimab or palivizumab resistance before and after the COVID-19 pandemic. However, RSV-specific drug-resistance substitutions for suptavumab were identified., Competing Interests: The authors have no potential conflicts of interest to disclose., (© 2024 The Korean Academy of Medical Sciences.)
- Published
- 2024
- Full Text
- View/download PDF
4. A Historical Perspective on Respiratory Syncytial Virus Prevention: A Journey Spanning Over Half a Century From the Setback of an Inactive Vaccine Candidate to the Success of Passive Immunization Strategy.
- Author
-
Noor A and Krilov LR
- Subjects
- Humans, History, 20th Century, History, 21st Century, Infant, Respiratory Syncytial Virus, Human immunology, Vaccines, Inactivated immunology, Vaccine Development, Antiviral Agents therapeutic use, Antiviral Agents administration & dosage, Immunoglobulins, Intravenous therapeutic use, Antibodies, Monoclonal therapeutic use, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Infections history, Respiratory Syncytial Virus Vaccines immunology, Respiratory Syncytial Virus Vaccines therapeutic use, Respiratory Syncytial Virus Vaccines administration & dosage, Immunization, Passive methods, Palivizumab therapeutic use
- Abstract
The efforts to prevent respiratory syncytial virus (RSV) infection in infants span over half a century. RSV vaccine development began in the 1960s, and it confronted a significant disappointment after testing a formalin-inactivated RSV (FI RSV) vaccine candidate. This inactivated RSV vaccine was not protective. A large number of the vaccinated RSV-naive children, when subsequently exposed to natural RSV infection from wild-type virus in the community, developed severe lung inflammation termed enhanced respiratory disease. This resulted in a halt in RSV vaccine development. In the 1990s, attention turned to the potential for passive protection against severe RSV disease with immunoglobulin administration. This led to studies on using standard intravenous immunoglobulins in high-risk infants, followed by high-titer RSV immunoglobulin preparation and, subsequently, the development of RSV monoclonal antibodies. Over the past 25 years, palivizumab has been recognized as a safe and effective monoclonal antibody as a prevention strategy for RSV in high-risk children. Its high cost and need for monthly administration, however, has hindered its use to ~2% of the birth cohort, neglecting the vast majority of newborns, including healthy full-term infants who comprise the largest portion of RSV hospitalizations and the greatest part of the burden of RSV disease. Still these efforts, helped pave the way for the present advances in RSV prevention that hold promise for mitigating severe RSV disease for all infants., (© The Author(s) 2024. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
5. RSV-Prophylaxe für alle Säuglinge.
- Author
-
Stief L
- Subjects
- Humans, Infant, Infant, Newborn, Antiviral Agents therapeutic use, Palivizumab therapeutic use, Respiratory Syncytial Virus Infections prevention & control
- Published
- 2024
- Full Text
- View/download PDF
6. Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced in Nicotiana benthamiana .
- Author
-
Pisuttinusart N, Rattanapisit K, Srisaowakarn C, Thitithanyanont A, Strasser R, Shanmugaraj B, and Phoolcharoen W
- Subjects
- Infant, Animals, Humans, Infant, Newborn, Aged, Palivizumab therapeutic use, Nicotiana genetics, Antibodies, Monoclonal therapeutic use, Antibodies, Viral, Antibodies, Neutralizing, Viral Fusion Proteins genetics, Mammals metabolism, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Vaccines
- Abstract
Respiratory syncytial virus (RSV) is a highly contagious virus that affects the lungs and respiratory passages of many vulnerable people. It is a leading cause of lower respiratory tract infections and clinical complications, particularly among infants and elderly. It can develop into serious complications such as pneumonia and bronchiolitis. The development of RSV vaccine or immunoprophylaxis remains highly active and a global health priority. Currently, GSK's Arexvy™ vaccine is approved for the prevention of lower respiratory tract disease in older adults (>60 years). Palivizumab and currently nirsevimab are the approved monoclonal antibodies (mAbs) for RSV prevention in high-risk patients. Many studies are ongoing to develop additional therapeutic antibodies for preventing RSV infections among newborns and other susceptible groups. Recently, additional antibodies have been discovered and shown greater potential for development as therapeutic alternatives to palivizumab and nirsevimab. Plant expression platforms have proven successful in producing recombinant proteins, including antibodies, offering a potential cost-effective alternative to mammalian expression platforms. Hence in this study, an attempt was made to use a plant expression platform to produce two anti-RSV fusion (F) mAbs 5C4 and CR9501. The heavy-chain and light-chain sequences of both these antibodies were transiently expressed in Nicotiana benthamiana plants using a geminiviral vector and then purified using single-step protein A affinity column chromatography. Both these plant-produced mAbs showed specific binding to the RSV fusion protein and demonstrate effective viral neutralization activity in vitro . These preliminary findings suggest that plant-produced anti-RSV mAbs are able to neutralize RSV in vitro .
- Published
- 2024
- Full Text
- View/download PDF
7. Respiratory syncytial virus immunization patterns in Germany, 2015-2020.
- Author
-
Wick M, Kliemt R, Poshtiban A, Kossack N, Diller GP, Soudani S, Bangert M, Kramer R, and Damm O
- Subjects
- Humans, Germany epidemiology, Infant, Female, Male, Health Care Costs statistics & numerical data, Infant, Newborn, Vaccination statistics & numerical data, Vaccination economics, Immunization statistics & numerical data, Birth Cohort, Child, Preschool, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections economics, Palivizumab administration & dosage, Palivizumab therapeutic use, Respiratory Syncytial Virus, Human immunology, Antiviral Agents economics, Antiviral Agents administration & dosage, Antiviral Agents therapeutic use
- Abstract
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children worldwide. Using routine statutory health insurance claims data including patients from all regions of Germany, we investigated the health-care resource use and costs associated with RSV prophylaxis with palivizumab in Germany. In the database, infants from the birth cohorts 2015-2019 eligible for palivizumab immunization were identified using codes of the 10
th revision of the International Classification of Diseases (ICD-10). Health-care resource use and costs related to immunization were determined by inpatient and outpatient administrations. Over the study period, only 1.3% of infants received at least one dose of palivizumab in their first year of life. The mean number of doses per immunized infant was 4.6. From a third-party payer perspective, the mean costs of palivizumab per infant who received at least one dose in the first year of life was €5,435 in the birth cohorts 2015-2019. Despite the substantial risk of severe RSV infection, we found low rates of palivizumab utilization. Novel preventive interventions, featuring broader indications and single-dose administration per season, contribute to mitigating the burden of RSV disease across a more extensive infant population.- Published
- 2024
- Full Text
- View/download PDF
8. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol.
- Author
-
Mallah N, Ares-Gómez S, Pardo-Seco J, Malvar-Pintos A, Santiago-Pérez MI, Pérez-Martínez O, Otero-Barrós MT, Suárez-Gaiche N, Kramer R, Jin J, Platero-Alonso L, Alvárez-Gil RM, Ces-Ozores OM, Nartallo-Penas V, Mirás-Carballal S, Piñeiro-Sotelo M, González-Pérez JM, Rodríguez-Tenreiro C, Rivero-Calle I, Salas A, Durán-Parrondo C, and Martinón-Torres F
- Subjects
- Humans, Infant, Respiratory Syncytial Virus, Human immunology, Female, Male, Respiratory Tract Infections prevention & control, Immunization Programs, Infant, Newborn, Child, Preschool, Palivizumab therapeutic use, Palivizumab administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Respiratory Syncytial Virus Infections prevention & control, Hospitalization statistics & numerical data, Antiviral Agents therapeutic use, Antiviral Agents administration & dosage
- Abstract
Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023. It aims to evaluate nirsevimab effectiveness against RSV-related hospitalizations lower respiratory tract infections (LRTI), severe RSV, all-cause LRTI, and all-cause hospitalization. NIRSE-GAL also aims to estimate nirsevimab impact on primary healthcare use in the short and mid-term, children's wheezing and asthma, and medical prescriptions for RSV. The immunization campaigns will be scheduled based on the expected start week for the RSV season and will last the whole season. Immunization will be offered to: i) infants born during the campaign (seasonal), ii) infants < 6 months at the start of the campaign (catch-up), and iii) infants with high-risk factors, aged 6-24 months at the start of the campaign (high-risk). The follow-up period will start: i) the immunization date for all immunized infants, ii) the start of the campaign, for the non-immunized catch-up or high-risk groups, or iii) the birthdate for the non-immunized seasonal group. Infants will be followed up until outcome occurrence, death, or end of study. Nirsevimab effectiveness will be estimated using Poisson and Cox regression models. Sensitivity and stratified analyses will be undertaken. The number of averted cases and the number needed to immunize will be estimated. Immunization failure and nirsevimab safety will be monitored. NIRSE-GAL was approved by the ethics committee of Galicia (CEIC 2023-377) and registered in ClinicalTrials.gov (ID: NCT06180993). Findings will be mainly shared via peer-reviewed publications and scientific conferences.
- Published
- 2024
- Full Text
- View/download PDF
9. Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).
- Author
-
Tuffy KM, Ahani B, Domachowske JB, Furuno K, Ji H, Madhi SA, Mankad VS, Hamrén UW, Villafana T, Wang Y, Kelly EJ, and Wilkins D
- Subjects
- Humans, Infant, Double-Blind Method, Male, Female, Infant, Newborn, Antibodies, Viral immunology, Child, Preschool, Antibodies, Neutralizing immunology, Antibodies, Neutralizing blood, Palivizumab therapeutic use, Palivizumab administration & dosage, Respiratory Syncytial Virus Infections prevention & control, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Antiviral Agents therapeutic use, Antiviral Agents administration & dosage, Respiratory Syncytial Virus, Human immunology, Respiratory Syncytial Virus, Human drug effects, Respiratory Syncytial Virus, Human genetics
- Abstract
Background: Nirsevimab is an extended half-life monoclonal antibody (mAb) licensed for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease in neonates, infants and medically vulnerable children. We characterized RSV isolates recovered from participants enrolled in MEDLEY: a randomized, palivizumab-controlled phase 2/3 trial of nirsevimab in infants born preterm and/or with congenital heart disease or chronic lung disease of prematurity., Methods: Participants were assessed in two RSV seasons (Season 1 and 2). Season 1 participants were randomized (2:1) to receive a single dose of nirsevimab (50 mg if weight <5 kg or 100 mg if weight ≥5 kg in Season 1; 200 mg in Season 2) followed by four monthly doses of placebo, or five once-monthly doses of palivizumab (15 mg/kg weight per dose). Season 2 participants continued nirsevimab and placebo (nirsevimab/nirsevimab) or were re-randomized (1:1) to switch to nirsevimab (palivizumab/nirsevimab) or continue palivizumab (palivizumab/palivizumab). Cases of RSV infection were identified by central testing of nasal swabs from participants seeking medical attention for respiratory illnesses. Nirsevimab and palivizumab binding site substitutions were assessed via microneutralization assay., Results: Twenty-five cases of confirmed RSV infection were observed during the trial and sequenced: 12 in nirsevimab recipients and 10 in palivizumab recipients during Season 1, and 1 case in each Season 2 group. Molecular sequencing of RSV A (n = 14) isolates detected no nirsevimab binding site substitutions, and 3 palivizumab neutralization-resistant substitutions (Lys272Met, Lys272Thr, Ser275Leu). The nirsevimab binding site Ile206Met:Gln209Arg and Ile206Met:Gln209Arg:Ser211Asn substitutions were the only anti-RSV mAb binding site substitutions detected among RSV B isolates (n = 11). Nirsevimab neutralized all nirsevimab and palivizumab binding site substitutions in RSV A and B isolates recovered from MEDLEY participants., Conclusion: No binding site substitution detected during MEDLEY affected RSV susceptibility to nirsevimab neutralization., Competing Interests: Declaration of competing interest Kevin M. Tuffy, Bahar Ahani, Hong Ji, Vaishali S. Mankad, Ulrika Wählby Hamrén, Tonya Villafana, Yingyi Wang and Deidre Wilkins are current employees of AstraZeneca and may hold AstraZeneca stock or stock options. Elizabeth J. Kelly is a former employee of AstraZeneca and a current employee of Sanofi and may hold stock or stock options for both institutions. Ulrika Wählby Hamrén, Tonya Villafana and Deidre Wilkins are named inventors on patents planned, issued or pending related to nirsevimab. Joseph B. Domachowske has received funding to their institution for the conduct of clinical trials from AstraZeneca, Merck and Regeneron, honoraria from Sanofi and has participated in advisory boards for GSK and Sanofi. Kenji Furuno has received honoraria from AstraZeneca and AbbVie. Shabir A. Madhi has received funding from AstraZeneca, Novavax, Providence, Gritstone and ImmunityBio for the conduct of clinical trials; institutional grants from the Bill and Malinda Gates Foundation, GSK, Pfizer and Minervax, honoraria from GSK and MSD and is a member of Data Safety Monitoring Boards for PATH and CAPRISA., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
10. Improvement in Palivizumab Administration Prior to Discharge for Hospitalized Infants with Hemodynamically Significant Congenital Heart Disease: A Quality Improvement Initiative.
- Author
-
Jones AL, Campbell MJ, Abernathy B, Neubert S, Hager A, Collier H, Ramsey EZ, Simon A, Schachtner S, and Natarajan S
- Subjects
- Humans, Infant, Female, Male, Patient Discharge, Infant, Newborn, Hemodynamics drug effects, Practice Guidelines as Topic, Hospitalization statistics & numerical data, Palivizumab administration & dosage, Palivizumab therapeutic use, Quality Improvement, Heart Defects, Congenital, Antiviral Agents administration & dosage, Antiviral Agents therapeutic use, Respiratory Syncytial Virus Infections prevention & control, Guideline Adherence statistics & numerical data
- Abstract
In this quality improvement initiative, we aimed to increase provider adherence with palivizumab administration guidelines for hospitalized infants with hemodynamically significant congenital heart disease. We included 470 infants over four respiratory syncytial virus (RSV) seasons from 11/2017 to 03/2021 (baseline season: 11/2017-03/2018). Interventions included the following: education, including palivizumab in the sign-out template, identifying a pharmacy expert, and a text alert (seasons 1 and 2: 11/2018-03/2020) that was replaced by an electronic health record (EHR) best practice alert (BPA) in season 3 (11/2020-03/2021). The text alert and BPA prompted providers to add "Need for RSV immunoprophylaxis" to the EHR problem list. The outcome metric was the percentage of eligible patients administered palivizumab prior to discharge. The process metric was the percentage of eligible patients with "Need for RSV immunoprophylaxis" on the EHR problem list. The balancing metric was the percentage of palivizumab doses administered to ineligible patients. A statistical process control P-chart was used to analyze the outcome metric. The mean percentage of eligible patients who received palivizumab prior to hospital discharge increased significantly from 70.1% (82/117) to 90.0% (86/96) in season 1 and to 97.9% (140/143) in season 3. Palivizumab guideline adherence was as high or higher for those with "Need for RSV immunoprophylaxis" on the problem list than for those without it in most time periods. The percentage of inappropriate palivizumab doses decreased from 5.7% (n = 5) at baseline to 4.4% (n = 4) in season 1 and 0.0% (n = 0) in season 3. Through this initiative, we improved adherence with palivizumab administration guidelines for eligible infants prior to hospital discharge., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
11. Nirsevimab: Reducing RSV Infections in Infants.
- Author
-
Murphy JFA
- Subjects
- Humans, Infant, Palivizumab therapeutic use, Palivizumab administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Antiviral Agents therapeutic use, Respiratory Syncytial Virus Infections prevention & control
- Abstract
Competing Interests: None declared
- Published
- 2024
12. Therapies to Decrease Severe Respiratory Syncytial Virus Illness.
- Author
-
Scruggs-Wodkowski EA, Malani PN, and Linder KA
- Subjects
- Humans, Infant, Palivizumab therapeutic use, Infant, Newborn, Child, Preschool, Aged, Child, Antibodies, Monoclonal, Humanized therapeutic use, Female, Pregnancy, Adult, Antiviral Agents therapeutic use, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Vaccines therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
13. Pediatric Respiratory Syncytial Virus Hospitalizations, 2017-2023.
- Author
-
Fitzpatrick T, Buchan SA, Mahant S, Fu L, Kwong JC, Stukel TA, and Guttmann A
- Subjects
- Humans, Infant, Male, Female, Child, Preschool, Ontario epidemiology, SARS-CoV-2, Intensive Care Units statistics & numerical data, Cohort Studies, Infant, Newborn, Respiration, Artificial statistics & numerical data, Pandemics, Palivizumab therapeutic use, Respiratory Syncytial Virus Infections epidemiology, Hospitalization statistics & numerical data, COVID-19 epidemiology
- Abstract
Importance: Respiratory syncytial virus (RSV) transmission was disrupted worldwide following the COVID-19 pandemic, and further study is required to better understand these changes., Objective: To compare observed and expected RSV hospital and intensive care unit (ICU) admission rates and characteristics of admitted children during the 2021-2022 and 2022-2023 seasons., Design, Setting, and Participants: A population-based cohort study of all children aged younger than 5 years in Ontario, Canada, July 1, 2017, through March 31, 2023, was conducted., Exposures: Individual and neighborhood-level sociodemographic and clinical characteristics were identified from administrative data, including age, palivizumab eligibility, complex medical conditions, rurality, and living in a marginalized neighborhood., Main Outcomes and Measures: The main outcome was RSV-associated hospitalization. Secondary outcomes included ICU admissions, mechanical ventilation, extracorporeal membrane oxygenation, and in-hospital death. Poisson generalized estimating equations were used to model weekly age- and sex-specific hospitalization rates and estimate expected rates in the postpandemic era; adjusted rate ratios (RRs) and 95% CIs are reported., Results: This cohort study included approximately 700 000 children per study year. Compared with prepandemic years (2017-2018, 2018-2019, and 2019-2020), the 2021-2022 RSV season peaked slightly earlier, but overall admission rates were comparable (289.1 vs 281.4-334.6 per 100 000, or approximately 2000 admissions). The 2022-2023 season peaked a month earlier and resulted in more than twice as many hospitalizations (770.0 per 100 000; n = 4977 admissions). The proportion of children admitted to an ICU in 2022-2023 (13.9%) was slightly higher than prepandemic (9.6%-11.4%); however, the population-based rate was triple the prepandemic levels (106.9 vs 27.6-36.6 per 100 000 children in Ontario). With the exception of palivizumab-eligible children, all sociodemographic and health status characteristics were associated with lower-than-expected RSV hospitalization rates in 2021-2022. In contrast, older age of patients was associated with higher-than-expected rates in 2022-2023 (ie, 24-59 months: RR, 1.90; 95% CI, 1.35-2.66)., Conclusions and Relevance: There were notable differences in RSV epidemiologic characteristics in Ontario following the COVID-19 pandemic. It is not yet clear whether and how long atypical RSV epidemics may persist. Clinicians and program planners should consider the potential for ongoing impacts to health care capacity and RSV immunization programs.
- Published
- 2024
- Full Text
- View/download PDF
14. RSVpreF (Abrysvo) and Nirsevimab-alip (Beyfortus) for the Prevention of Respiratory Syncytial Virus Infection.
- Author
-
Nodelman M and Scott AM
- Subjects
- Humans, Antibodies, Monoclonal, Humanized therapeutic use, Infant, Palivizumab therapeutic use, Viral Vaccines, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections prevention & control, Antiviral Agents therapeutic use
- Published
- 2024
15. Management and outcomes of bronchiolitis in Italy and Latin America: a multi-center, prospective, observational study.
- Author
-
Camporesi A, Yock-Corrales A, Gomez-Vargas J, Roland D, Gonzalez M, Barreiro S, Morello R, Brizuela M, and Buonsenso D
- Subjects
- Humans, Italy epidemiology, Prospective Studies, Infant, Male, Female, Latin America epidemiology, Infant, Newborn, Treatment Outcome, Hospitalization statistics & numerical data, Child, Preschool, Palivizumab therapeutic use, Bronchiolitis epidemiology, Bronchiolitis therapy, Bronchiolitis drug therapy
- Abstract
We aimed to describe differences in the epidemiology, management, and outcomes existing between centers located in countries which differ by geographical location and economic status during to post-pandemic bronchiolitis seasons. This was a prospective observational cohort study performed in two academic centers in Latin America (LA) and three in Italy. All consecutive children with a clinical diagnosis of bronchiolitis were included, following the same data collection form. Nine hundred forty-three patients have been enrolled: 275 from the two Latin American Centers (San Jose, 215; Buenos Aires, 60), and 668 from Italy (Rome, 178; Milano, 163; Bologna, 251; Catania, 76). Children in LA had more frequently comorbidities, and only rarely received palivizumab. A higher number of patients in LA had been hospitalized in a ward (64% versus 23.9%, p < 0.001) or in a PICU (16% versus 6.2%, p < 0.001), and children in LA required overall more often respiratory support, from low flow oxygen to invasive mechanical ventilation, except for CPAP which was more used in Italy. There was no significant difference in prescription rates for antibiotics, but a significantly higher number of patients treated with systemic steroids in Italy., Conclusions: We found significant differences in the care for children with bronchiolitis in Italy and LA. Reasons behind such differences are unclear and would require further investigations to optimize and homogenize practice all over the world., What Is Known: • Bronchiolitis is among the commest cause of morbidity and mortality in infants all over the world., What Is New: • There are significant differences on how clinicians care for bronchiolitis in different centers and continents. Differences in care can be principally due to different local practices than differences in patients severity/presentations. • Understanding these differences should be a priority to optime and standardize bronchiolitis care globally., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
16. Früh im Leben vor RSV schützen.
- Author
-
Hofmann-Aßmus M
- Subjects
- Humans, Infant, Infant, Newborn, Antibodies, Monoclonal, Humanized therapeutic use, Antiviral Agents therapeutic use, Palivizumab therapeutic use, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections prevention & control
- Published
- 2024
- Full Text
- View/download PDF
17. Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro.
- Author
-
Lekic E, Dragas L, Nikcevic D, Lekic J, Dedic A, and Sulovic L
- Subjects
- Humans, Male, Infant, Female, Infant, Newborn, Prospective Studies, Retrospective Studies, Montenegro epidemiology, Infant, Premature, Palivizumab therapeutic use, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Infections epidemiology, Antiviral Agents therapeutic use
- Abstract
Background: Respiratory syncytial virus (RSV) is one of the most common pathogens causing severe lower respiratory tract disease in infancy and childhood. In newborns, young infants, and in infants with co-morbidities, the risk of severe infection is increased. Current protection against severe RSV infection is immunoprophylaxis with the monoclonal antibody palivizumab. The study aimed to assess the effects of palivizumab prophylaxis in the Republic of Montenegro in comparison to the pre-prophylaxis period., Methods: The study was conducted in prospective/retrospective single center format in Montenegro in the Clinical Center of Podgorica, for the period 2009-2019., Results: A total of 104 high-risk infants in the palivizumab prophylaxis program (2014-2019 RSV seasons) and 168 high-risk children without palivizumab prophylaxis (2009-2013 RSV seasons) were enrolled. A total of 51 children (49.0%) received prophylaxis for prematurity, 33 (31.7%) for bronchopulmonary dysplasia (BPD), 13 (12.5%) for hemodynamically significant heart disease/defect (HSCHD), and 7 (6.8%) for "miscellaneous" indications. In the control group most children had prematurity (101, 60.1%), followed by BPD (59, 35.1%), HSCHD (3, 1.8%), and "miscellaneous" (5, 3.4%) conditions. Readmission to the pediatric intensive care units (PICU) due to RSV infection was significantly lower in prophylaxis group (0.0 vs 16.1%, p<0.001). No lethal outcomes were observed in high-risk children with palivizumab prophylaxis compared to 2.4% in the control group., Conclusions: The introduction of RSV immunoprophylaxis as well as other new protective treatment strategies for high-risk newborns led to significant improvements in infant and childcare in Montenegro. This is the first report on palivizumab prophylaxis in Montenegro, demonstrating the effectiveness and safety of palivizumab use in clinical settings., Competing Interests: The authors declare that there is no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
18. Cost Savings Without Increased Risk of Respiratory Hospitalization for Preterm Children after the 2014 Palivizumab Policy Update.
- Author
-
Levin JC, Beam AL, Fox KP, and Hayden LP
- Subjects
- Humans, Infant, Newborn, Male, Female, Infant, United States, Health Policy, Respiratory Tract Infections prevention & control, Seasons, Gestational Age, Palivizumab therapeutic use, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Infections epidemiology, Hospitalization statistics & numerical data, Infant, Premature, Antiviral Agents therapeutic use, Antiviral Agents economics, Interrupted Time Series Analysis, Cost Savings
- Abstract
Objectives: Our objective was to compare rates of hospitalizations for respiratory illnesses in preterm and full-term (FT) children for 4 years before and after the 2014 update to the American Academy of Pediatrics (AAP) respiratory syncytial virus (RSV) immunoprophylaxis guidance, which restricted eligibility among infants born at 29 to 34 weeks in the first winter and all preterm infants in the second winter after neonatal discharge., Study Design: We conducted pre-post and interrupted time series analyses on claims data from a commercial national managed care plan. We compared the number of RSV and all respiratory hospital admissions in the first and second RSV seasons after neonatal discharge among a cohort of preterm children, regardless of palivizumab status, in the 4 years before and after the implementation of the 2014 palivizumab eligibility change. A FT group was included for reference., Results: The cohort included 821 early preterm (EP, <29 weeks), 4,790 moderate preterm (MP, 29-34 weeks), and 130,782 FT children. Palivizumab use after the policy update decreased among MP children in the first and second RSV seasons after neonatal discharge, without any change in the odds of hospitalization with RSV or respiratory illness. For the EP group, there was no change in the rate of palivizumab or the odds of hospitalization with RSV or respiratory illness after the policy update. For the FT group, there was a slight decrease in odds of hospitalization post-2014 after the policy update. The interrupted time series did not reveal any secular trends over time in hospitalization rates among preterm children. Following the policy change, there were cost savings for MP children in the first and second RSV seasons, when accounting for the cost of hospitalizations and the cost of palivizumab., Conclusion: Hospitalizations for RSV or respiratory illness did not increase, and cost savings were obtained after the implementation of the 2014 AAP palivizumab prophylaxis policy., Key Points: · Palivizumab use decreased among children born moderate preterm (29 to34 weeks) after the 2014 palivizuamb policy update.. · There was no change in odds of hospitalization with respiratory syncitial virus or respiratory illness among preterm infants after the policy update when compared to before.. · There were cost savings, when accounting for the cost of hospitalizations and the cost of palivizumab, after the policy update among children born moderate preterm.., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.
- Author
-
Gonzales T, Bergamasco A, Cristarella T, Goyer C, Wojdyla M, Oladapo A, Sawicky J, Yee J, and Moride Y
- Subjects
- Humans, Infant, Infant, Newborn, Hospitalization statistics & numerical data, Bronchopulmonary Dysplasia prevention & control, Heart Defects, Congenital complications, Respiration, Artificial, Respiratory Tract Infections prevention & control, Observational Studies as Topic, Clinical Trials, Phase III as Topic, Palivizumab therapeutic use, Respiratory Syncytial Virus Infections prevention & control, Antiviral Agents therapeutic use, Infant, Premature
- Abstract
Objective: Palivizumab is a humanized monoclonal antibody approved for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in infants and young children at high risk of RSV disease. This systematic review summarized evidence on the effectiveness and safety of palivizumab when used in approved populations., Study Design: A systematic review of Phase III trials and observational studies was conducted according to the population, intervention, comparator, outcome, timing, setting (PICOTS) approach (PROSPERO, CRD42021281380). Target populations consisted of infants with a history of premature birth (≤35-week gestational age) and children aged <2 years with bronchopulmonary dysplasia (BPD) or with hemodynamically significant congenital heart disease (hs-CHD). Outcomes of interest included RSV-related hospitalization, admission to intensive care unit (ICU), requirement for mechanical ventilation, treatment-related adverse events (AEs), and RSV-related deaths. Information sources were literature search (Ovid MEDLINE and Embase), pragmatic searches, and snowballing (covering the period up to 07 September 2021)., Results: A total of 60 sources were included (5 Phase III trials and 55 observational studies). RSV-related hospitalization rates following palivizumab prophylaxis in Phase III trials were 1.8% in premature infants and 7.9% in children with BPD, which were significantly lower than rates in placebo arms. In the real-world setting, similar hospitalization rates were found (0.7-4.0% in premature infants [16 studies] and 0-5.5% in patients with BPD [10 studies]) with ICU admission reported in 0 to 33.3% of patients hospitalized for RSV. In Phase III trials, RSV-related mortality rates were 0.2 and 0.3%, while AEs occurred in 11% of premature and/or BPD patients and 7.2% of hs-CHD patients, consisting mainly of injection site reaction, fever, and diarrhea. Similar results were found in observational studies., Conclusion: This systematic review supports the effectiveness and safety of palivizumab in the indicated populations., Key Points: · Systematic review supports the positive benefit-risk profile of palivizumab in the indicated populations.. · Real-world safety and effectiveness of palivizumab are consistent with Phase III trials results.. · Palivizumab reduces RSV-related hospitalizations, ICU admissions, and need for mechanical ventilation.., Competing Interests: A.B., T.C., C.G., and Y.M. are employees of YOLARX Consultants that received funding from Sobi for the conduct of this review. T.G., A.O., J.S., J.Y., and M.W. are employees of Sobi., (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)
- Published
- 2024
- Full Text
- View/download PDF
20. Exploratory analysis of the economically justifiable price of nirsevimab for healthy late-preterm and term infants in Colombia.
- Author
-
Buendía JA, Acuña-Cordero R, and Rodriguez-Martinez CE
- Subjects
- Humans, Colombia, Infant, Infant, Newborn, Infant, Premature, Antiviral Agents economics, Antiviral Agents therapeutic use, Cost-Benefit Analysis, Antibodies, Monoclonal, Humanized economics, Antibodies, Monoclonal, Humanized therapeutic use, Palivizumab therapeutic use, Palivizumab economics, Female, Male, Respiratory Syncytial Virus Infections economics, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections prevention & control, Quality-Adjusted Life Years
- Abstract
Introduction: Respiratory syncytial virus infection is the leading cause of lower respiratory infection globally. Recently, nirsevimab has been approved to prevent respiratory syncytial virus (RSV) infection. This study explores the economically justifiable price of nirsevimab for preventing RSV infection in Colombia's children under 1 year of age., Materials and Methods: A static model was developed using the decision tree microsimulation to estimate the quality-adjusted costs and life years of two interventions: a single intramuscular dose of nirsevimab versus not applying nirsevimab. This analysis was made during a time horizon of 1 year and from a societal perspective., Results: The annual savings in Colombia associated with this cost per dose ranged from U$ 2.5 to 4.1 million. Based on thresholds of U$ 4828, U$ 5128, and U$ 19 992 per QALY evaluated in this study, we established economically justifiable drug acquisition prices of U$ 21.88, U$ 25.04, and U$ 44.02 per dose of nirsevimab., Conclusion: the economically justifiable cost for nirsevimab in Colombia is between U$ 21 to U$ 44 per dose, depending on the willingness to pay used to decide its implementation. This result should encourage more studies in the region that optimize decision-making processes when incorporating this drug into the health plans of each country., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
21. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
- Author
-
Ordóñez JE and Huertas VM
- Subjects
- Infant, Infant, Newborn, Humans, Palivizumab therapeutic use, Cost-Benefit Analysis, Colombia epidemiology, Antiviral Agents therapeutic use, Infant, Premature, Antibodies, Monoclonal, Humanized therapeutic use, Hospitalization, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus, Human, Heart Defects, Congenital
- Abstract
Aim: Palivizumab has proven effective in reducing hospitalizations, preventing severe illness, improving health outcomes, and reducing healthcare costs for infants at risk of respiratory syncytial virus (RSV) infection. We aim to assess the value of palivizumab in preventing RSV infection in high-risk infants in Colombia, where RSV poses a significant threat, causing severe respiratory illness and hospitalizations., Methods: We conducted a decision tree analysis to compare five doses of palivizumab with no palivizumab. The study considered three population groups: preterm neonates (≤ 35 weeks gestational age), infants with bronchopulmonary dysplasia (BPD), and infants with hemodynamically significant congenital heart disease (CHD). We obtained clinical efficacy data from IMpact-RSV and Cardiac Synagis trials, while we derived neonatal hospitalization risks from the SENTINEL-1 study. We based hospitalization and recurrent wheezing management costs on Colombian analyses and validated them by experts. We estimated incremental cost-effectiveness ratios and performed 1,000 Monte Carlo simulations for probabilistic sensitivity analyses., Results: Palivizumab is a dominant strategy for preventing RSV infection in preterm neonates and infants with BPD and CHD. Its high efficacy (78% in preventing RSV in preterm infants), the substantial risk of illness and hospitalization, and the high costs associated with hospitalization, particularly in neonatal intensive care settings, support this finding. The scatter plots and willingness-to-pay curves align with these results., Conclusion: Palivizumab is a cost-saving strategy in Colombia, effectively preventing RSV infection in preterm neonates and infants with BPD and CHD by reducing hospitalizations and lowering healthcare costs., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
22. Balanced on the Biggest Wave: Nirsevimab for Newborns.
- Author
-
McPherson C, Lockowitz CR, and Newland JG
- Subjects
- Humans, Infant, Newborn, Antiviral Agents therapeutic use, Heart Defects, Congenital, Infant, Premature, Palivizumab therapeutic use, United States, Randomized Controlled Trials as Topic, Antibodies, Monoclonal, Humanized, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections prevention & control
- Abstract
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development. Monoclonal antibodies reduce the risk of hospitalization from severe RSV disease, with palivizumab protecting high-risk newborns with comorbidities including chronic lung disease and congenital heart disease. Unfortunately, palivizumab is costly and requires monthly administration of up to five doses during the RSV season for optimal protection.Rapid advances in the past two decades have facilitated the identification of antibodies with broad neutralizing activity and allowed manipulation of their genetic code to extend half-life. These advances have culminated with nirsevimab, a monoclonal antibody targeting the Ø antigenic site on the RSV prefusion protein and protecting infants from severe disease for an entire 5-month season with a single dose. Four landmark randomized controlled trials, the first published in July 2020, have documented the efficacy and safety of nirsevimab in healthy late-preterm and term infants, healthy preterm infants, and high-risk preterm infants and those with congenital heart disease. Nirsevimab reduces the risk of RSV disease requiring medical attention (number needed to treat [NNT] 14-24) and hospitalization (NNT 33-63) with rare mild rash and injection site reactions. Consequently, the Centers for Disease Control and Prevention has recently recommended nirsevimab for all infants younger than 8 months of age entering or born during the RSV season and high-risk infants 8-19 months of age entering their second season. Implementing this novel therapy in this large population will require close multidisciplinary collaboration. Equitable distribution through minimizing barriers and maximizing uptake must be prioritized., (© Copyright 2024 Springer Publishing Company, LLC.)
- Published
- 2024
- Full Text
- View/download PDF
23. An epidemiological investigation of high-risk infants for Respiratory Syncytial Virus infections: a retrospective cohort study.
- Author
-
Servadio M, Finocchietti M, Vassallo C, Cipelli R, Heiman F, Di Lucchio G, Oresta B, Addis A, and Belleudi V
- Subjects
- Infant, Infant, Newborn, Humans, Infant, Premature, Retrospective Studies, Cohort Studies, Palivizumab therapeutic use, Hospitalization, Antiviral Agents therapeutic use, Respiratory Syncytial Virus Infections prevention & control, Heart Defects, Congenital epidemiology, Bronchopulmonary Dysplasia epidemiology
- Abstract
Background: Respiratory Syncytial Virus (RSV) infections may lead to severe consequences in infants born preterm with breathing problems (such as bronchopulmonary dysplasia (BPD) and respiratory distress syndrome (RDS)) or congenital heart diseases (CHD). Since studies investigating the influence of different gestational age (WGA) and concomitant specific comorbidities on the burden of RSV infections are scarce, the present study aimed to better characterize these high-risk populations in the Italian context., Methods: This retrospective, longitudinal and record-linkage cohort study involved infants born between 2017 and 2019 in Lazio Region (Italy) and is based on data extracted from administrative databases. Each infant was exclusively included in one of the following cohorts: (1) BPD-RDS (WGA ≤35 with or without CHD) or (2) CHD (without BPD and/or RDS) or (3) Preterm (WGA ≤35 without BPD (and/or RDS) or CHD). Each cohort was followed for 12 months from birth. Information related to sociodemographic at birth, and RSV and Undetermined Respiratory Agents (URA) hospitalizations and drug consumption at follow-up were retrieved and described., Results: A total of 8,196 infants were selected and classified as 1,084 BPD-RDS, 3,286 CHD and 3,826 Preterm. More than 30% of the BPD-RDS cohort was composed by early preterm infants (WGA ≤ 29) in contrast to the Preterm cohort predominantly constitute by moderate preterm infants (98.2%), while CHD infants were primarily born at term (83.9%). At follow-up, despite the cohorts showed similar proportions of RSV hospitalizations, in BPD-RDS cohort hospitalizations were more frequently severe compared to those occurred in the Preterm cohort (p<0.01), in the BPD-RDS cohort was also found the highest proportion of URA hospitalizations (p<0.0001). In addition, BPD-RDS infants, compared to those of the remaining cohorts, received more frequently prophylaxis with palivizumab (p<0.0001) and were more frequently treated with adrenergics inhalants, and glucocorticoids for systemic use., Conclusions: The assessment of the study clinical outcomes highlighted that, the demographic and clinical characteristics at birth of the study cohorts influence their level of vulnerability to RSV and URA infections. As such, continuous monitoring of these populations is necessary in order to ensure a timely organization of health care system able to respond to their needs in the future., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
24. Palivizumab prophylaxis in preterm infants and subsequent wheezing/asthma: 10-year follow-up study.
- Author
-
Kato M, Mochizuki H, Kama Y, Kusuda S, Okada K, Yoshihara S, Furuya H, and Simões EAF
- Subjects
- Infant, Infant, Newborn, Humans, Palivizumab therapeutic use, Infant, Premature, Follow-Up Studies, Antiviral Agents therapeutic use, Prospective Studies, Case-Control Studies, Respiratory Sounds diagnosis, Hospitalization, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Infections drug therapy, Asthma epidemiology, Asthma prevention & control, Asthma drug therapy, Respiratory Syncytial Virus, Human
- Abstract
Background: Respiratory syncytial virus (RSV) causes not only infantile recurrent wheezing but also the development of asthma. To investigate whether palivizumab, an anti-RSV monoclonal antibody, prophylaxis given to preterm infants during the first RSV season reduces the incidence of subsequent recurrent wheezing and/or development of asthma, at 10 years of age., Methods: We conducted an observational prospective multicenter (52 registered hospitals in Japan) case-control study in preterm infants with a gestational age between 33 and 35 weeks followed for 6 years. During the 2007-2008 RSV season, the decision to administer palivizumab was made based on standard medical practice (SCELIA study). Here, we followed these subjects until 10 years of age. Parents of study subjects reported the patients' physician's assessment of recurrent wheezing/asthma, using a report card and a novel mobile phone-based reporting system using the internet. The relationship between RSV infection and asthma development, as well as the relationship between other factors and asthma development, were investigated., Results: Of 154 preterm infants enrolled, 113 received palivizumab during the first year of life. At 10 years, although both recurrent wheezing and development of asthma were not significantly different between the treated and untreated groups, maternal smoking with aeroallergen sensitization of the patients was significantly correlated with physician-diagnosed asthma., Conclusions: In contrast to the prior study results at 6 years, by 10 years palivizumab prophylaxis had no impact on recurrent wheezing or asthma, but there was a significant correlation between maternal passive smoking with aeroallergen sensitization and development of asthma by 10 years of age., (© 2023 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
25. Inhaled "Muco-Trapping" Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections.
- Author
-
McSweeney MD, Alnajjar S, Schaefer AM, Richardson Z, Wolf W, Stewart I, Sriboonyapirat P, McCallen J, Farmer E, Nzati B, Lord S, Farrer B, Moench TR, Kumar PA, Arora H, Pickles RJ, Hickey AJ, Ackermann M, and Lai SK
- Subjects
- Humans, Infant, Child, Animals, Sheep, Mice, Aged, Palivizumab therapeutic use, Respiratory Syncytial Viruses, Lung, Antibodies, Monoclonal therapeutic use, Respiratory Syncytial Virus Infections drug therapy
- Abstract
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in infants, the immunocompromised, and the elderly. RSV infects the airway epithelium via the apical membrane and almost exclusively sheds progeny virions back into the airway mucus (AM), making RSV difficult to target by systemically administered therapies. An inhalable "muco-trapping" variant of motavizumab (Mota-MT), a potent neutralizing mAb against RSV F is engineered. Mota-MT traps RSV in AM via polyvalent Fc-mucin bonds, reducing the fraction of fast-moving RSV particles in both fresh pediatric and adult AM by ≈20-30-fold in a Fc-glycan dependent manner, and facilitates clearance from the airways of mice within minutes. Intranasal dosing of Mota-MT eliminated viral load in cotton rats within 2 days. Daily nebulized delivery of Mota-MT to RSV-infected neonatal lambs, beginning 3 days after infection when viral load is at its maximum, led to a 10 000-fold and 100 000-fold reduction in viral load in bronchoalveolar lavage and lung tissues relative to placebo control, respectively. Mota-MT-treated lambs exhibited reduced bronchiolitis, neutrophil infiltration, and airway remodeling than lambs receiving placebo or intramuscular palivizumab. The findings underscore inhaled delivery of muco-trapping mAbs as a promising strategy for the treatment of RSV and other acute respiratory infections., (© 2024 The Authors. Advanced Science published by Wiley‐VCH GmbH.)
- Published
- 2024
- Full Text
- View/download PDF
26. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks' gestation in the United States.
- Author
-
Yu T, Padula WV, Yieh L, and Gong CL
- Subjects
- Infant, Infant, Newborn, Humans, United States, Pregnancy, Female, Palivizumab therapeutic use, Cost-Benefit Analysis, Gestational Age, Antiviral Agents therapeutic use, Respiratory Syncytial Viruses, Hospitalization, Infant, Premature, Respiratory Syncytial Virus Infections prevention & control, Antibodies, Monoclonal, Humanized
- Abstract
Background: Respiratory syncytial virus (RSV) hospitalizations have increased since the 2014 guideline update recommended against the use of palivizumab for preterm infants born ≥29 0/7 weeks' gestational age (GA) without additional risk factors. A novel drug candidate, nirsevimab, has been developed for this population. We analyzed the cost-effectiveness of palivizumab/nirsevimab vs. no prophylaxis in this population., Methods: A hybrid-Markov model predicted the RSV clinical course in the first year of life and sequelae in the subsequent four years for preterm infants from the healthcare and societal perspectives. Model parameters were derived from the literature. We calculated costs and quality-adjusted life-years (QALYs) to produce an incremental cost-effectiveness ratio (ICER) evaluated at a willingness-to-pay threshold of $150,000/QALY. Sensitivity analyses assessed model robustness. A threshold analysis examined nirsevimab pricing uncertainty., Results: Compared to no prophylaxis, palivizumab costs $9572 and $9584 more from the healthcare and societal perspectives, respectively, with 0.0019 QALYs gained per patient over five years, resulting in ICERs >$5 million per QALY from each perspective. Results were robust to parameter uncertainties; probabilistic sensitivity analysis revealed that no prophylaxis had a 100% probability of being cost-effective. The threshold analysis suggested that nirsevimab is not cost-effective when compared to no prophylaxis if the price exceeds $1962 from a societal perspective., Conclusion: Palivizumab is dominated by no prophylaxis for preterm infants 29 0/7-34 6/7 weeks' GA with no additional risk factors. Relevant stakeholders should consider alternatives to palivizumab for this population that are both effective and economical., Competing Interests: Conflict of interest T. Yu reported receiving personal fees from AbbVie outside the submitted work., (Copyright © 2024 Taiwan Pediatric Association. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date.
- Author
-
Verwey C, Dangor Z, and Madhi SA
- Subjects
- Pregnancy, United States, Child, Infant, Female, Humans, Palivizumab therapeutic use, Antibodies, Monoclonal therapeutic use, European Union, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections prevention & control, Vaccines
- Abstract
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that include vaccines and long-acting, high-potency monoclonal antibodies. Nirsevimab (Beyfortus™-AstraZeneca/Sanofi), a monoclonal antibody with an extended half-life, has recently been registered in the European Union and granted licensure by the US Food and Drug Administration. Furthermore, a pre-fusion sub-unit protein vaccine has been granted licensure for pregnant women, aimed at protecting their young infants, following established safety and efficacy in clinical trials (Abrysvo™-Pfizer). Also, multiple novel antiviral therapeutic options are in early phase clinical trials. The next few years have the potential to change the landscape of LRTI through improvements in the prevention and management of RSV LRTI. Here, we discuss these new approaches, current research, and clinical trials in novel therapeutics, monoclonal antibodies, and vaccines against RSV infection in infants and children., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
28. Efficacy of Palivizumab Immunoprophylaxis for Reducing Severe RSV Outcomes in Children with Immunodeficiencies: A Systematic Review.
- Author
-
Reicherz F, Abu-Raya B, Akinseye O, Rassekh SR, Wiens MO, and Lavoie PM
- Subjects
- Child, Humans, Antibodies, Monoclonal, Humanized therapeutic use, Hospitalization, Palivizumab therapeutic use, Respiratory Syncytial Viruses, Antiviral Agents therapeutic use, Immunologic Deficiency Syndromes complications, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections prevention & control
- Abstract
Background: Palivizumab is recommended for prevention of severe respiratory syncytial virus (RSV) disease in immunocompromised children, despite a lack of strong supporting evidence. The recent approval of substitute RSV-neutralizing monoclonal antibodies against RSV, offers an opportunity to synthesize the most current evidence supporting the palivizumab standard of care., Objective: To evaluate the efficacy of palivizumab in preventing acute respiratory tract infection- or RSV-related hospitalization, or mortality in immunocompromised children., Methods: We searched Ovid MEDLINE and EMBASE for published clinical studies that investigated outcomes of palivizumab use in children. We included clinical trials, cohort studies, and case-control studies. The primary outcomes were RSV-related or respiratory viral infection-related hospitalizations, or RSV-related mortality. This systematic review was registered in PROSPERO (ID CRD42021248619) and is reported in accordance with the PRISMA guidelines., Results: From the 1993 records, six studies were eligible and included, for a total of 625 immunocompromised children with an heterogeneous composition of primary and acquired immunodeficiencies enrolled from palivizumab programs. There were no intervention studies. None of the studies included a control group. RSV hospitalizations were infrequent (0%-3.1% of children). Most children included received palivizumab, although one study (n = 56) did not specify how many received palivizumab. RSV mortality was neither observed, in three studies, nor reported, in three other studies., Conclusions: The evidence supporting the use of palivizumab for prevention of severe RSV disease in immunocompromised children remains extremely limited and appears insufficient to justify prioritizing this intervention as the current standard of care over alternative interventions., (© The Author(s) 2024. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
29. A molecular perspective for the development of antibodies against the human respiratory syncytial virus.
- Author
-
Loaiza RA, Ramírez RA, Sepúlveda-Alfaro J, Ramírez MA, Andrade CA, Soto JA, González PA, Bueno SM, and Kalergis AM
- Subjects
- Infant, Child, Humans, Aged, Antiviral Agents therapeutic use, Palivizumab therapeutic use, Antibodies, Monoclonal therapeutic use, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections prevention & control
- Abstract
The human respiratory syncytial virus (hRSV) is the leading etiologic agent causing respiratory infections in infants, children, older adults, and patients with comorbidities. Sixty-seven years have passed since the discovery of hRSV, and only a few successful mitigation or treatment tools have been developed against this virus. One of these is immunotherapy with monoclonal antibodies against structural proteins of the virus, such as Palivizumab, the first prophylactic approach approved by the Food and Drug Administration (FDA) of the USA. In this article, we discuss different strategies for the prevention and treatment of hRSV infection, focusing on the molecular mechanisms against each target that underly the rational design of antibodies against hRSV. At the same time, we describe the latest results regarding currently approved therapies against hRSV and the challenges associated with developing new candidates., Competing Interests: Declaration of competing interest The authors declare the following possible conflict of interest: Dr. Alexis Kalergis has a patent ‘Monoclonal Antibody specific against the antigen N of the Human Respiratory Syncytial Virus (VRSH), useful for the treatment of infection, its detection, and diagnosis: PCT/CL 2018/050,079, date of presentation September 2018. The authors report no other conflicts of interest in this work., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
- Author
-
Cieslak CM
- Subjects
- Infant, Child, Humans, United States, Palivizumab therapeutic use, Respiratory Syncytial Viruses, Antibodies, Monoclonal therapeutic use, Antiviral Agents therapeutic use, Hospitalization, Immunization, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections prevention & control, Respiratory Tract Infections drug therapy, Respiratory Tract Infections prevention & control, Respiratory Tract Infections chemically induced, Antibodies, Monoclonal, Humanized
- Abstract
Respiratory syncytial virus (RSV) infects nearly all infants in their first year of life and is the leading cause of hospitalization for infants younger than 1 year of age in the United States. Historically, the only option for RSV prevention was palivizumab. However, not all infants are eligible for palivizumab, it requires multiple doses per RSV season, and it is costly. In July 2023, the U.S. Food and Drug Administration approved nirsevimab for the prevention of RSV-associated lower respiratory tract infections for all infants. Nirsevimab inhibits RSV from fusing to cellular membranes and thereby neutralizes the virus in the body. Nirsevimab is expected to significantly reduce the health and economic burdens of RSV. This article provides an overview of nirsevimab, potential adverse effects, and implications for nursing practice., (Copyright © 2023 AWHONN. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Society for Maternal-Fetal Medicine Statement: Clinical considerations for the prevention of respiratory syncytial virus disease in infants.
- Author
-
Joseph NT, Kuller JA, Louis JM, and Hughes BL
- Subjects
- Infant, Child, Pregnancy, Female, Humans, Palivizumab therapeutic use, Respiratory Syncytial Viruses, Antibodies, Monoclonal therapeutic use, Antiviral Agents therapeutic use, Perinatology, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Infections drug therapy
- Abstract
Respiratory syncytial virus is a leading cause of lower respiratory tract illness globally in children aged <5 years. Each year, approximately 58,000 hospitalizations in the United States are attributed to respiratory syncytial virus. Infants aged ≤6 months experience the most severe morbidity and mortality. Until recently, prevention with the monoclonal antibody, palivizumab, was only offered to infants with high-risk conditions, and treatment primarily consisted of supportive care. Currently, 2 products are approved for the prevention of respiratory syncytial virus in infants. These include the Pfizer bivalent recombinant respiratory syncytial virus prefusion F protein subunit vaccine, administered seasonally to the pregnant person between 32 0/7 and 36 6/7 weeks of gestation, and the monoclonal antibody, nirsevimab, administered to infants aged up to 8 months entering their first respiratory syncytial virus season. With few exceptions, administering both the vaccine to the pregnant person and the monoclonal antibody to the infant is not recommended. All infants should be protected against respiratory syncytial virus using one of these strategies. Key considerations for pregnant individuals include examining available safety and efficacy data, weighing accessibility and availability, and patient preferences for maternal vaccination vs infant monoclonal antibody treatment. It will be critical for maternal-fetal medicine physicians to provide effective and balanced counseling to aid patients in deciding on a personalized approach to the prevention of respiratory syncytial virus in their infants., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
32. Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus.
- Author
-
Sun BW, Zhang PP, Wang ZH, Yao X, He ML, Bai RT, Che H, Lin J, Xie T, Hui Z, Ye XY, and Wang LW
- Subjects
- Humans, Infant, Aged, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, Palivizumab pharmacology, Palivizumab therapeutic use, Anti-Retroviral Agents therapeutic use, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections prevention & control
- Abstract
Respiratory syncytial virus (RSV) is a significant viral pathogen that causes respiratory infections in infants, the elderly, and immunocompromised individuals. RSV-related illnesses impose a substantial economic burden worldwide annually. The molecular structure, function, and in vivo interaction mechanisms of RSV have received more comprehensive attention in recent times, and significant progress has been made in developing inhibitors targeting various stages of the RSV replication cycle. These include fusion inhibitors, RSV polymerase inhibitors, and nucleoprotein inhibitors, as well as FDA-approved RSV prophylactic drugs palivizumab and nirsevimab. The research community is hopeful that these developments might provide easier access to knowledge and might spark new ideas for research programs.
- Published
- 2024
- Full Text
- View/download PDF
33. RSV Prevention - Breakthroughs and Challenges.
- Author
-
Halasa NB
- Subjects
- Humans, Palivizumab therapeutic use, Antiviral Agents therapeutic use, Respiratory Syncytial Virus Infections prevention & control
- Published
- 2023
- Full Text
- View/download PDF
34. Cost-effectiveness of prophylaxis with palivizumab among high-risk children in Hong Kong: abridged secondary publication.
- Author
-
Wu P, Cowling BJ, Chiu SS, Wong IOL, and Yeung WKY
- Subjects
- Child, Humans, Infant, Palivizumab therapeutic use, Cost-Benefit Analysis, Hong Kong, Hospitalization, Antiviral Agents therapeutic use, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections prevention & control
- Published
- 2023
35. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023.
- Author
-
Martinón-Torres F, Mirás-Carballal S, and Durán-Parrondo C
- Subjects
- Infant, Humans, Antibodies, Monoclonal therapeutic use, Palivizumab therapeutic use, Spain, Respiratory Syncytial Viruses, Antiviral Agents therapeutic use, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus, Human
- Abstract
A monoclonal antibody for universal respiratory syncytial virus prophylaxis in infants has recently been licensed. We share our experiences of integrating nirsevimab into the regional immunisation programme in Galicia, Spain. After a 3-week hospital-based immunisation campaign with flexible individualised appointments and educational activities, nirsevimab uptake was 97.5% in the high-risk group, 81.4% in the catch-up group and 92.6% in infants born during the campaign. This successful implementation strategy can serve as a model and may inform other countries' programmatic deliberations.
- Published
- 2023
- Full Text
- View/download PDF
36. Respiratory syncytial virus-approved mAb Palivizumab as ligand for anti-idiotype nanobody-based synthetic cytokine receptors.
- Author
-
Ettich J, Wittich C, Moll JM, Behnke K, Floss DM, Reiners J, Christmann A, Lang PA, Smits SHJ, Kolmar H, and Scheller J
- Subjects
- Humans, Palivizumab pharmacology, Palivizumab therapeutic use, Receptors, Cytokine, Cytokines, Ligands, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, Receptors, Artificial metabolism, Receptors, Artificial therapeutic use, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus, Human
- Abstract
Synthetic cytokine receptors can modulate cellular functions based on an artificial ligand to avoid off-target and/or unspecific effects. However, ligands that can modulate receptor activity so far have not been used clinically because of unknown toxicity and immunity against the ligands. Here, we developed a fully synthetic cytokine/cytokine receptor pair based on the antigen-binding domain of the respiratory syncytial virus-approved mAb Palivizumab as a synthetic cytokine and a set of anti-idiotype nanobodies (AIP
VHH ) as synthetic receptors. Importantly, Palivizumab is neither cross-reactive with human proteins nor immunogenic. For the synthetic receptors, AIPVHH were fused to the activating interleukin-6 cytokine receptor gp130 and the apoptosis-inducing receptor Fas. We found that the synthetic cytokine receptor AIPVHH gp130 was efficiently activated by dimeric Palivizumab single-chain variable fragments. In summary, we created an in vitro nonimmunogenic full-synthetic cytokine/cytokine receptor pair as a proof of concept for future in vivo therapeutic strategies utilizing nonphysiological targets during immunotherapy., Competing Interests: Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
37. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection.
- Author
-
Brady T, Cayatte C, Roe TL, Speer SD, Ji H, Machiesky L, Zhang T, Wilkins D, Tuffy KM, and Kelly EJ
- Subjects
- Infant, Humans, Animals, Palivizumab therapeutic use, Antibodies, Viral, Complement System Proteins therapeutic use, Sigmodontinae, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections
- Abstract
Introduction: Nirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified) monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus (RSV) Fusion protein, with established efficacy in preventing RSV-associated lower respiratory tract infection in infants for the duration of a typical RSV season. Previous studies suggest that nirsevimab confers protection via direct virus neutralization. Here we use preclinical models to explore whether fragment crystallizable (Fc)-mediated effector functions contribute to nirsevimab-mediated protection., Methods: Nirsevimab, MEDI8897* (i.e., nirsevimab without the YTE modification), and MEDI8897*-TM (i.e., MEDI8897* without Fc effector functions) binding to Fc γ receptors (FcγRs) was evaluated using surface plasmon resonance. Antibody-dependent neutrophil phagocytosis (ADNP), antibody-dependent cellular phagocytosis (ADCP), antibody-dependent complement deposition (ADCD), and antibody-dependent cellular cytotoxicity (ADCC) were assessed through in vitro and ex vivo serological analyses. A cotton rat challenge study was performed with MEDI8897* and MEDI8897*-TM to explore whether Fc effector functions contribute to protection from RSV., Results: Nirsevimab and MEDI8897* exhibited binding to a range of FcγRs, with expected reductions in FcγR binding affinities observed for MEDI8897*-TM. Nirsevimab exhibited in vitro ADNP, ADCP, ADCD, and ADCC activity above background levels, and similar ADNP, ADCP, and ADCD activity to palivizumab. Nirsevimab administration increased ex vivo ADNP, ADCP, and ADCD activity in participant serum from the MELODY study (NCT03979313). However, ADCC levels remained similar between nirsevimab and placebo. MEDI8897* and MEDI8897*-TM exhibited similar dose-dependent reduction in lung and nasal turbinate RSV titers in the cotton rat model., Conclusion: Nirsevimab possesses Fc effector activity comparable with the current standard of care, palivizumab. However, despite possessing the capacity for Fc effector activity, data from RSV challenge experiments illustrate that nirsevimab-mediated protection is primarily dependent on direct virus neutralization., Competing Interests: The authors of this manuscript are current or former employees of AstraZeneca and may hold AstraZeneca stock or stock options. The authors declare that this study received funding from AstraZeneca and Sanofi. The funders had the following involvement with the study: study design; collection, analysis and interpretation of data; the writing of this article and the decision to submit it for publication., (Copyright © 2023 Brady, Cayatte, Roe, Speer, Ji, Machiesky, Zhang, Wilkins, Tuffy and Kelly.)
- Published
- 2023
- Full Text
- View/download PDF
38. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
- Author
-
Kong AM, Winer IH, Zimmerman NM, Diakun D, Bloomfield A, Gonzales T, Fergie J, Goldstein M, and Krilov LR
- Subjects
- Infant, Female, Infant, Newborn, Humans, Child, United States epidemiology, Infant, Premature, Antiviral Agents therapeutic use, Retrospective Studies, Hospitalization, Gestational Age, Palivizumab therapeutic use, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus, Human, Bronchiolitis
- Abstract
Objective: In 2014, the American Academy of Pediatrics (AAP) changed its policy on the use of respiratory syncytial virus immunoprophylaxis (RSV-IP) so that RSV-IP was no longer recommended for use among infants without other medical conditions born >29 weeks of gestational age (wGA). This study examines 10-year trends in RSV-IP and RSV hospitalizations among term infants and preterm infants born at 29 to 34 wGA, including the 5 RSV seasons before and 5 RSV seasons after the AAP guidance change., Study Design: A retrospective observational cohort study of a convenience sample of infants less than 6 months of age during RSV season (November-March) born between July 1, 2008, and June 30, 2019, who were born at 29 to 34 wGA (preterm) or >37 wGA (term) in the IBM MarketScan Commercial and Multi-State Medicaid databases. We excluded infants with medical conditions that would independently qualify them for RSV-IP. We identified RSV-IP utilization along with RSV and all-cause bronchiolitis hospitalizations during each RSV season. A difference-in-difference model was used to determine if there was a significant change in the relative rate of RSV hospitalizations following the 2014 policy change., Results: There were 53,535 commercially insured and 85,099 Medicaid-insured qualifying preterm infants and 1,111,670 commercially insured and 1,492,943 Medicaid-insured qualifying term infants. Following the 2014 policy change, RSV-IP utilization decreased for all infants, while hospitalization rates tended to increase for preterm infants. Rate ratios comparing preterm to term infants also increased. The relative rate for RSV hospitalization for infants born at 29 to 34 wGA increased significantly for both commercially and Medicaid-insured infants (1.95, 95% CI: 1.67-2.27, p <0.001; 1.70, 95% CI: 1.55-1.86, p <0.001, respectively). Findings were similar for all-cause bronchiolitis hospitalizations., Conclusion: We found that the previously identified increase in RSV hospitalization rates among infants born at 29 to 34 wGA persisted for at least 5 years following the policy change., Key Points: · Immunoprophylaxis rates decreased after the 2014 American Academy of Pediatrics guidelines update.. · Rate of RSV hospitalization increased among preterm infants after the 2014 AAP guidelines update.. · Increase in RSV hospitalization persisted for at least 5 years after AAP guidelines update.., Competing Interests: A.B. is currently employed by Moderna, Cambridge, MA, and was employed by Sobi at the time this study was conducted. T.G. is employed by Sobi. A.M.K. is currently employed by Aetion, New York, NY, and was employed by IBM Watson Health at the time this study was conducted. I.H.W., N.M.Z., and D.D. are employed by IBM Watson Health, which received funding from Sobi to conduct this study. L.R.K. has received research funding to their institution from Pfizer and Astra Zeneca, along with consultant fees from Pfizer and Sobi. J.F. has received grant/research support from AstraZeneca/MedImmune and is a member of the AstraZeneca and Sobi speaker's bureau. M.G. is employed at an institution that has received research funding from AstraZeneca., (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)
- Published
- 2023
- Full Text
- View/download PDF
39. Wastewater-based surveillance identifies start to the pediatric respiratory syncytial virus season in two cities in Ontario, Canada.
- Author
-
Mercier E, Pisharody L, Guy F, Wan S, Hegazy N, D'Aoust PM, Kabir MP, Nguyen TB, Eid W, Harvey B, Rodenburg E, Rutherford C, Mackenzie AE, Willmore J, Hui C, Paes B, Delatolla R, and Thampi N
- Subjects
- Humans, Child, Palivizumab therapeutic use, Antiviral Agents therapeutic use, Ontario epidemiology, Wastewater-Based Epidemiological Monitoring, Seasons, Cities, Wastewater, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections drug therapy
- Abstract
Introduction: Detection of community respiratory syncytial virus (RSV) infections informs the timing of immunoprophylaxis programs and hospital preparedness for surging pediatric volumes. In many jurisdictions, this relies upon RSV clinical test positivity and hospitalization (RSVH) trends, which are lagging indicators. Wastewater-based surveillance (WBS) may be a novel strategy to accurately identify the start of the RSV season and guide immunoprophylaxis administration and hospital preparedness., Methods: We compared citywide wastewater samples and pediatric RSVH in Ottawa and Hamilton between August 1, 2022, and March 5, 2023. 24-h composite wastewater samples were collected daily and 5 days a week at the wastewater treatment facilities in Ottawa and Hamilton, Ontario, Canada, respectively. RSV WBS samples were analyzed in real-time for RSV by RT-qPCR., Results: RSV WBS measurements in both Ottawa and Hamilton showed a lead time of 12 days when comparing the WBS data set to pediatric RSVH data set (Spearman's ρ = 0.90). WBS identify early RSV community transmission and declared the start of the RSV season 36 and 12 days in advance of the provincial RSV season start (October 31) for the city of Ottawa and Hamilton, respectively. The differing RSV start dates in the two cities is likely associated with geographical and regional variation in the incidence of RSV between the cities., Discussion: Quantifying RSV in municipal wastewater forecasted a 12-day lead time of the pediatric RSVH surge and an earlier season start date compared to the provincial start date. These findings suggest an important role for RSV WBS to inform regional health system preparedness, reduce RSV burden, and understand variations in community-related illness as novel RSV vaccines and monoclonal antibodies become available., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Mercier, Pisharody, Guy, Wan, Hegazy, D’Aoust, Kabir, Nguyen, Eid, Harvey, Rodenburg, Rutherford, Mackenzie, Willmore, Hui, Paes, Delatolla and Thampi.)
- Published
- 2023
- Full Text
- View/download PDF
40. Respiratory syncytial virus and its prophylaxis with palivizumab: exploring nurses' knowledge.
- Author
-
Moore E and Hughes M
- Subjects
- Infant, Child, Humans, Palivizumab therapeutic use, Respiratory Syncytial Viruses, Antiviral Agents therapeutic use, Clinical Competence, Hospitalization, Nurses, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus Infections prevention & control
- Abstract
Background: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in children. Premature infants and infants with underlying health issues are at increased risk of developing severe RSV infection. Prophylactic treatment with palivizumab reduces their risk of hospitalisation., Aim: To measure nurses' knowledge of RSV and RSV prophylaxis and explore their perceived potential barriers to palivizumab administration to children in the acute hospital setting., Method: A non-experimental, quantitative fixed study design was adopted. A 17-item online questionnaire was used to survey nurses caring for children under the age of 1 year in an acute children's teaching hospital., Results: Questionnaires were completed by 144 nurses, giving a response rate of 53%. Respondents demonstrated an adequate knowledge of RSV and its prophylaxis but also some knowledge deficits, notably about the eligibility criteria for palivizumab. The most cited perceived potential barriers to palivizumab administration were uncertainty about which infants are eligible for it, forgetting to check whether a patient is due to receive a dose, parental refusal for treatment because their child is ill, and not knowing the contraindications of palivizumab., Conclusion: Front-line hospital staff have a crucial role in identifying infants eligible for prophylactic RSV treatment, in initiating prophylaxis in a timely manner, in avoiding missed or delayed palivizumab doses during infants' hospital stays, and in educating families about the importance of RSV prevention., Competing Interests: None declared, (© 2023 RCN Publishing Company Ltd. All rights reserved. Not to be copied, transmitted or recorded in any way, in whole or part, without prior permission of the publishers.)
- Published
- 2023
- Full Text
- View/download PDF
41. In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections.
- Author
-
Ramirez KA, Mond J, Papenburg J, Boivin G, Gilbert BE, Falsey AR, Bagga B, and DeVincenzo JP
- Subjects
- Humans, Immunocompromised Host, Animals, Sigmodontinae, Lung pathology, Lung virology, Immunoglobulins administration & dosage, Antibodies, Neutralizing administration & dosage, Female, Infant, Fatal Outcome, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications, Palivizumab therapeutic use, Respiratory Syncytial Virus, Human drug effects, Respiratory Syncytial Virus Infections drug therapy, Drug Resistance, Viral
- Abstract
Background: Monoclonal antibody (palivizumab), intravenous immune globulin (IGIV), or respiratory syncytial virus (RSV)-polyclonal-hyperimmune-globulin (RSV-IG as Respigam®, RI-001, RI-002) are used with ribavirin in RSV-infected immunocompromised patients, with debated efficacy. Palivizumab-resistance (PR) can arise during treatment of persistent infections in this population. RSV-IG may confer benefit in PR-RSV infection., Methods: RSV-IG [RI-001] was provided for an immunocompromised infant with RSV-pneumonitis refractory to ribavirin and palivizumab. RSV-neutralizing antibody, respiratory RSV load (qPCR), and F-gene-sequence-detection of PR was determined. Prophylactic RSV-IG [RI-002] or palivizumab was administered in a cotton-rat model infected with wild-type and PR-RSV. Lung RSV load and neutralizing antibody were measured., Results: As protective RI-001-neutralizing antibody titers waned in the infant, a subpopulation of PR-escape mutants were detected with a fatal RSV-burden in the lungs. In PR-RSV-infected cotton rats, prophylactic RI-002 reduced RSV-load in the lungs (2.45 vs 0.28 log
10 PFU/g lung-tissue reduction, respectively, p < 0.05) and provided protective RSV-neutralizing antibody., Conclusions: RSV-IG and ribavirin use in immunocompromised patients requires further study., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier Inc.)- Published
- 2023
- Full Text
- View/download PDF
42. Determining the true incidence of seasonal respiratory syncytial virus-confirmed hospitalizations in preterm and term infants in Western Australia.
- Author
-
Sarna M, Gebremedhin A, Richmond P, Levy A, Glass K, and Moore HC
- Subjects
- Humans, Infant, Newborn, Infant, Infant, Premature, Incidence, Western Australia epidemiology, Seasons, Hospitalization, Palivizumab therapeutic use, Antiviral Agents therapeutic use, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus, Human
- Abstract
Respiratory syncytial virus contributes to significant global infant morbidity and mortality. We applied a previously developed statistical prediction model incorporating pre-pandemic RSV testing data and hospital admission data to estimate infant RSV-hospitalizations by birth month and prematurity, focused on infants aged <1 year. The overall predicted RSV-hospitalization incidence rates in infants <6 months were 32.7/1,000 child-years (95 % CI: 31.8, 33.5) and 3.1/1,000 child-years (95 % CI: 3.0, 3.1) in infants aged 6-<12 months. Predicted RSV-hospitalization rates for infants aged <6 months were highest for infants born in April/May. Predicted rates for preterm infants born 29-32 weeks gestation were highest in March-May, whereas infants born >33 weeks had peak RSV-hospitalization rates from May-June, similar to late preterm or term births. RSV-hospitalization rates in the pre-pandemic era were highly seasonal, and seasonality varied with degree of prematurity. Accurate estimates of RSV-hospitalization in high-risk sub-groups are essential to understand preventable burden of RSV especially given the current prevention landscape., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
43. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
- Author
-
Keary IP, Ravasio R, Fullarton JR, Manzoni P, Lanari M, Paes BA, Carbonell-Estrany X, Baraldi E, Tarride JÉ, and Rodgers-Gray B
- Subjects
- Infant, Newborn, Infant, Humans, Palivizumab therapeutic use, Cost-Benefit Analysis, Gestational Age, Antiviral Agents therapeutic use, Infant, Premature, Antibodies, Monoclonal, Humanized therapeutic use, Risk Factors, Hospitalization, Italy epidemiology, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus, Human
- Abstract
Since the last Italian cost-utility assessment of palivizumab in 2009, new data on the burden of respiratory syncytial virus (RSV) and an International Risk Scoring Tool (IRST) have become available. The objective of this study was to provide an up-to-date cost-utility assessment of palivizumab versus no prophylaxis for the prevention of severe RSV infection in otherwise healthy Italian infants born at 29-31 weeks' gestational age (wGA) infants and those 32-35wGA infants categorized as either moderate- or high-risk of RSV-hospitalization (RSVH) by the IRST. A decision tree was constructed in which infants received palivizumab or no prophylaxis and then could experience: i) RSVH; ii) emergency room medically-attended RSV-infection (MARI); or, iii) remain uninfected/non-medically attended. RSVH cases that required intensive care unit admission could die (0.43%). Respiratory morbidity was considered in all surviving infants up to 18 years of age. Hospitalization rates were derived from Italian data combined with efficacy from the IMpact-RSV trial. Palivizumab costs were calculated from vial prices (50mg: €490.37 100mg: €814.34) and Italian birth statistics combined with a growth algorithm. A lifetime horizon and healthcare and societal costs were included. The incremental cost-utility ratio (ICUR) was €14814 per quality-adjusted life year (QALY) gained in the whole population (mean: €15430; probability of ICUR being <€40000: 0.90). The equivalent ICURs were €15139 per QALY gained (€15915; 0.89) for 29-31wGA infants and €14719 per QALY gained (€15230; 0.89) for 32-35wGA infants. The model was most sensitive to rates of long-term sequelae, utility scores, palivizumab cost, and palivizumab efficacy. Palivizumab remained cost-effective in all scenario analyses, including a scenario wherein RSVH infants received palivizumab without a reduction in long-term sequelae and experienced a 6-year duration of respiratory morbidity (ICUR: €27948 per QALY gained). In conclusion, palivizumab remains cost-effective versus no prophylaxis in otherwise healthy Italian preterm infants born 29-35wGA. The IRST can help guide cost-effective use of palivizumab in 32-35wGA infants., Competing Interests: BP, EB, PM, ML, XCE have received research funding and/or compensation as advisor/lecturer from AstraZeneca and/or Sanofi and/or Pfizer outside the scope of this study. BRG, IK, JF, and RR employers have received payment from AstraZeneca for work on various projects. JET has nothing to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials., (Copyright: © 2023 Keary et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
44. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
- Author
-
Packnett ER, Winer IH, Oladapo A, and Wojdyla M
- Subjects
- Infant, Infant, Newborn, Humans, Child, United States, Palivizumab therapeutic use, Gestational Age, Antiviral Agents therapeutic use, Outpatients, Hospitalization, Infant, Premature, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections prevention & control
- Abstract
Palivizumab has been shown to decrease RSV-related hospitalization (RSVH) risk and reduce RSVH severity. American Academy of Pediatrics (AAP) guidance on administration of palivizumab has changed over time; in 2014, palivizumab was no longer recommended in preterm infants born at 29 weeks gestational age (wGA) or later. This study's objective was to describe RSVH risk and severity in preterm infants (29-34 wGA) without comorbidities relative to healthy term infants and to each other by gestational age. Using the MarketScan Multi-State Medicaid and Commercial Databases, infants born from July 1, 2014 to June 30, 2019, at 29-34 wGA (preterm) and >37 wGA (term) were identified. During RSV seasons (November to March) from 2014 to 2020, claims incurred by infants while they were <6 months old were evaluated for RSVH and RSVH characteristics. This study included 63,351 preterm infants and 1,076,389 term infants without outpatient palivizumab administration. Rate of RSVH was higher in infants with lower wGA at birth and ranged 3.32-5.72 per 100 infant-seasons in Medicaid-insured infants and 3.21-4.84 in commercially insured infants. Relative risk of RSVH was 5-8 times higher in Medicaid-insured preterm infants and 3-5 times higher in commercially insured preterm infants compared to term infants. ICU admissions and mechanical ventilation were more common during RSVH in preterm infants relative to term infants. RSV-related outpatient healthcare utilization was also 2-3 times higher in preterm infants born at 31-34 wGA. Increased utilization of palivizumab among infants born at 29-34 wGA may decrease RSVH rates and result in less severe course in preterm infants with RSVH.
- Published
- 2023
- Full Text
- View/download PDF
45. Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection.
- Author
-
Caserta MT, O'Leary ST, Munoz FM, and Ralston SL
- Subjects
- Infant, Child, Humans, Child, Preschool, Palivizumab therapeutic use, Antiviral Agents therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Respiratory Syncytial Viruses, Hospitalization, Respiratory Syncytial Virus Infections epidemiology
- Abstract
Guidance from the American Academy of Pediatrics (AAP) for the use of palivizumab prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement in 1998. AAP recommendations have been updated periodically to reflect the most recent literature regarding children at greatest risk of severe RSV disease. Since the last update in 2014, which refined prophylaxis guidance to focus on those children at greatest risk, data have become available regarding the seasonality of RSV circulation, the incidence and risk factors associated with bronchiolitis hospitalizations, and the potential effects of the implementation of prophylaxis recommendations on hospitalization rates of children with RSV infection. This technical report summarizes the literature review by the Committee on Infectious Diseases, supporting the reaffirmation of the 2014 AAP policy statement on palivizumab prophylaxis among infants and young children at increased risk of hospitalization for RSV infection. Review of publications since 2014 did not support a change in recommendations for palivizumab prophylaxis and continues to endorse the guidance provided in the 2021 Red Book., Competing Interests: FINANCIAL/CONFLICT OF INTEREST DISCLOSURE: Dr Munoz has disclosed data safety monitoring board relationships with Pfizer and Moderna for RSV vaccine, a data safety monitor board relationship with Moderna for vaccines inclusive of RSV and COVID-19, and consultant relationships with Sanofi and Aztra-Zeneca for RSV monoclonal antibody products. Her consultant relationships with Sanofi and Aztra-Zeneca initiated after her involvement with the writing of this technical report. An independent bias review of this document did not determine any concerns for bias., (Copyright © 2023 by the American Academy of Pediatrics.)
- Published
- 2023
- Full Text
- View/download PDF
46. Respiratory Syncytial Virus Bronchiolitis: Rapid Evidence Review.
- Author
-
Oppenlander KE, Chung AA, and Clabaugh D
- Subjects
- Child, Child, Preschool, Humans, Infant, Bronchodilator Agents, Palivizumab therapeutic use, Respiratory Syncytial Viruses, Bronchiolitis therapy, Bronchiolitis drug therapy, Respiratory Syncytial Virus Infections diagnosis, Respiratory Syncytial Virus Infections prevention & control
- Abstract
Bronchiolitis is the most common lower respiratory tract infection in young children. Respiratory syncytial virus (RSV) is the most common viral cause of bronchiolitis. RSV is spread through respiratory droplets, and the number of cases varies with season. For most patients, standard precautions (e.g., hand hygiene, surface cleaning, avoiding contact with sick individuals) are recommended. However, prophylaxis with palivizumab may be considered for infants at high risk. Initial symptoms occur after an incubation period of four to six days and include rhinorrhea, congestion, sneezing, and fever. Signs of lower respiratory tract involvement may follow and include cough, tachypnea, retractions, difficulty feeding, and accessory muscle use. Diagnosis is typically clinical; routine use of radiography or viral testing is not recommended. Treatment of RSV bronchiolitis is mainly supportive. Oxygen saturation should be maintained above 90%. Hydration and nutrition should be maintained by nasogastric or intravenous routes, if needed. Therapies such as bronchodilators, epinephrine, nebulized hypertonic saline, corticosteroids, antibiotics, and chest physiotherapy are not recommended. Although most episodes of RSV bronchiolitis are self-limited, some children have an increased risk of asthma later in life.
- Published
- 2023
47. The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs.
- Author
-
Roy Á, Polazzi S, Ploin D, Gillet Y, Javouhey E, Lina B, Myard-Dury AF, Couray-Targe S, Duclos A, and Casalegno JS
- Subjects
- Infant, Child, Humans, Aged, Child, Preschool, Palivizumab therapeutic use, Antiviral Agents therapeutic use, Pandemics, Hospitalization, Respiratory Syncytial Virus Infections epidemiology, COVID-19 epidemiology, Respiratory Syncytial Virus, Human
- Abstract
Background: Preventive measures applied during the COVID-19 pandemic have modified the age distribution, the clinical severity and the incidence of Respiratory Syncytial Virus (RSV) hospitalisations during the 2020/21 RSV season. The aim of the present study was to estimate the impact of these aspects on RSV-associated hospitalisations (RSVH) costs stratified by age group between pre-COVID-19 seasons and 2020/21 RSV season., Methods: We compared the incidence, the median costs, and total RSVH costs from the national health insurance perspective in children < 24 months of age during the COVID-19 period (2020/21 RSV season) with a pre-COVID-19 period (2014/17 RSV seasons). Children were born and hospitalised in the Lyon metropolitan area. RSVH costs were extracted from the French medical information system (Programme de Médicalisation des Systémes d'Information)., Results: The RSVH-incidence rate per 1000 infants aged < 3 months decreased significantly from 4.6 (95 % CI [4.1; 5.2]) to 3.1 (95 % CI [2.4; 4.0]), and increased in older infants and children up to 24 months of age during the 2020/21 RSV season. Overall, RSVH costs for RSVH cases aged below 2 years old decreased by €201,770 (31 %) during 2020/21 RSV season compared to the mean pre-COVID-19 costs., Conclusions: The sharp reduction in costs of RSVH in infants aged < 3 months outweighed the modest increase in costs observed in the 3-24 months age group. Therefore, conferring a temporal protection through passive immunisation to infants aged < 3 months should have a major impact on RSVH costs even if it results in an increase of RSVH in older children infected later in life. Nevertheless, stakeholders should be aware of this potential increase of RSVH in older age groups presenting with a wider range of disease to avoid any bias in estimating the cost-effectiveness of passive immunisation strategies., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: J.S.C participated as an expert to Pfizer scientific advisory board and in PROMISE General Assembly. J.S.C. did not receive funding for these activities., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
48. Hospitalization for bronchiolitis in children aged ≤ 1year, Southern Italy, year 2021: need for new preventive strategies?
- Author
-
Baldassarre ME, Loconsole D, Centrone F, Caselli D, Martire B, Quartulli L, Acquafredda A, D'Amato G, Maffei G, Latorre G, Riganti A, Di Noia M, Chironna M, and Laforgia N
- Subjects
- Infant, Newborn, Infant, Humans, Child, Palivizumab therapeutic use, Antiviral Agents therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Hospitalization, Italy epidemiology, Bronchiolitis epidemiology, Bronchiolitis prevention & control, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections prevention & control
- Abstract
Background: Bronchiolitis is a major cause of hospitalization in infants, particularly in the first six months of life, with approximately 60-80% of admissions due to respiratory syncytial virus (RSV) infection. Currently, no prophylactic options are available for healthy infants. The present study aimed at describing the demographic, clinical, and epidemiological characteristics of infants hospitalized for bronchiolitis in the Apulia region of Italy in 2021., Methods: From January to December 2021, data on children aged 0-12 months admitted for bronchiolitis in nine neonatal or pediatric units covering 61% of pediatric beds of hospitals in the Apulia region of Italy were analyzed. Demographic data, comorbidities, need for oxygen support, length of hospital stay, palivizumab administration, and outcomes were collected. For the purpose of the analysis, patients were divided into those aged 0-3 months and > 3 months. A multivariate logistic regression model was used to explore associations between the need for oxygen support and sex, age, comorbidities, history of prematurity, length of hospital stay, and palivizumab administration., Results: This study included 349 children aged 0-12 months admitted for bronchiolitis, with a peak of hospitalization in November (7.4 cases/1,000 children). Of these patients, 70.5% were RSV positive, 80.2% were aged 0-3 months, and 73.1% required oxygen support. Moreover, 34.9% required observation in the sub-intensive care unit, and 12.9% in the intensive care unit. Of the infants who required intensive care, 96.9% were aged 0-3 months and 78.8% were born at term. Three patients required mechanical ventilation and one, who required Extra Corporeal Membrane Oxygenation, died. Children aged 0-3 months were more likely to show dyspnea, need oxygen support, and have a longer hospital stay., Conclusions: The present study showed that almost all of the children who required intensive care support were aged ≤ 3 months and most were born at term. Therefore, this age group remains the highest risk group for severe bronchiolitis. Preventive measures such as single-dose monoclonal antibody immunoprophylaxis, and maternal and childhood vaccination against RSV, may reduce the high public health burden of bronchiolitis., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
49. RSV through the COVID-19 pandemic: Burden, shifting epidemiology, and implications for the future.
- Author
-
Stein RT and Zar HJ
- Subjects
- Child, Humans, Infant, Antiviral Agents therapeutic use, Pandemics prevention & control, Palivizumab therapeutic use, COVID-19 epidemiology, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Infections drug therapy, Respiratory Syncytial Virus, Human
- Abstract
Respiratory syncytial virus (RSV) represents a major global healthcare burden, particularly in those under 5 years of age. There is no available vaccine, with treatment limited to supportive care or palivizumab for high-risk children. Additionally, although a causal relationship has not been established, RSV has been associated with the development of asthma or wheezing in some children. The COVID-19 pandemic and the introduction of nonpharmaceutical interventions (NPIs) have caused substantial changes to RSV seasonality and epidemiology. Many countries have experienced an absence of RSV during the time of a typical season, followed by an out-of-season surge upon relaxation of NPI use. These dynamics have disrupted traditional RSV disease patterns and assumptions, but also provide a unique opportunity to learn more about the transmission of RSV and other respiratory viruses, as well as inform future approaches to RSV preventive strategies. Here, we review the RSV burden and epidemiology through the COVID-19 pandemic and discuss how new data may affect future decisions regarding RSV prevention., (© 2023 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
50. Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein.
- Author
-
Bergeron HC, Murray J, Arora A, Nuñez Castrejon AM, DuBois RM, Anderson LJ, Kauvar LM, and Tripp RA
- Subjects
- Mice, Humans, Animals, Aged, Palivizumab therapeutic use, Antibodies, Viral, Viral Fusion Proteins, Antibodies, Monoclonal therapeutic use, Epitopes, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections prevention & control
- Abstract
The respiratory syncytial virus (RSV) causes significant respiratory disease in young infants and the elderly. Immune prophylaxis in infants is currently limited to palivizumab, an anti-RSV fusion (F) protein monoclonal antibody (mAb). While anti-F protein mAbs neutralize RSV, they are unable to prevent aberrant pathogenic responses provoked by the RSV attachment (G) protein. Recently, the co-crystal structures of two high-affinity anti-G protein mAbs that bind the central conserved domain (CCD) at distinct non-overlapping epitopes were solved. mAbs 3D3 and 2D10 are broadly neutralizing and block G protein CX3C-mediated chemotaxis by binding antigenic sites γ1 and γ2, respectively, which is known to reduce RSV disease. Previous studies have established 3D3 as a potential immunoprophylactic and therapeutic; however, there has been no similar evaluation of 2D10 available. Here, we sought to determine the differences in neutralization and immunity to RSV Line19F infection which recapitulates human RSV infection in mouse models making it useful for therapeutic antibody studies. Prophylactic (24 h prior to infection) or therapeutic (72 h post-infection) treatment of mice with 3D3, 2D10, or palivizumab were compared to isotype control antibody treatment. The results show that 2D10 can neutralize RSV Line19F both prophylactically and therapeutically, and can reduce disease-causing immune responses in a prophylactic but not therapeutic context. In contrast, 3D3 was able to significantly ( p < 0.05) reduce lung virus titers and IL-13 in a prophylactic and therapeutic regimen suggesting subtle but important differences in immune responses to RSV infection with mAbs that bind distinct epitopes.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.